Drugmaker AstraZeneca has paused the trial of a potential coronavirus vaccine developed by Oxford University over risks of a “potentially dangerous illness” stemming from the use of the treatment, NBC News reports.
The Oxford virus uses an adenovirus virus to depress the production of a protein the coronavirus manipulates to infect the human body.
“Our standard review process was triggered and we voluntarily paused vaccination to allow review of safety data by an independent committee,” the company said in a statement. “This is a routine action which has to happen whenever there is a potentially unexplained illness in one of the trials, while it is investigated, ensuring we maintain the integrity of the trials.”